TABLE 2.

Predictive tool for ESBL-EB BSI among solid organ transplant recipients

	Variable	aOR	95% CI	P value	Points
Colonization or infection with EB organisms in prior 12 mo	ESBL-EB organism isolated on prior culture	29.70	13.10-67.30	<.01	5
	E. coli isolated on prior culture	0.92	0.41-2.06	.85	−1
	EB organism isolated from prior urinary culture	0.55	0.26-1.18	.12	−2
Antimicrobial exposures in prior 6 mo	Third-generation cephalosporin	2.87	1.46-5.63	<.01	3
	Trimethoprim-sulfamethoxazole	1.81	1.01-3.24	.05	2
	Aminoglycoside	1.16	0.38-3.55	.79	1
Severity of illness in prior 48 h	Mechanical ventilation	1.72	0.81-3.66	.16	2
	Hypotensiona	1.06	0.77-1.45	.72	1
Immunosuppressive regimen	Receipt of non-corticosteroid immunomodulator in prior 30 db	1.45	0.83-2.56	.19	2
	Corticosteroid-containing chronic immunosuppressive regimenc	1.44	0.83-2.48	.19	2

Abbreviations: aOR, adjusted odds ratio; BSI, bloodstream infection; CI, confidence interval; EB, Enterobacterales; ESBL, extended-spectrum beta-lactamase.

^aDefined by a drop in systolic blood pressure of > 30 mm Hg and diastolic blood pressure of > 20 mm Hg, requirement for vasopressor, or systolic blood pressure < 90 mm Hg.

^bReceipt of any of the following agents in the 30 d preceding EB BSI: abatacept, anakinra, apremilast, azathioprine, cyclophosphamide, cyclosporine, denosumab, hydroxychloroquine, methotrexate, mycophenolate, rituximab, secukinumab, sulfasalazine, tocilizumab, tofacitinib, infliximab, adalimumab, certolizumab, golimumab, or etanercept.

^cAssessed at the time of EB BSI, including any corticosteroid dose.